{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:34:02Z","timestamp":1782329642021,"version":"3.54.5"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Anti\u2013double-stranded DNA (dsDNA) antibody has been reported to have a close relationship with systemic lupus erythematosus (SLE) flares and participates in the pathogenesis of lupus nephritis (LN) as well as causing damage to other organs. However, whether early use of mycophenolate mofetil (MMF) could prevent SLE flares is not clear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the efficacy and safety of MMF plus prednisone and hydroxychloroquine sulfate compared with prednisone and hydroxychloroquine sulfate alone in patients with SLE.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This investigator-initiated, multicenter, observer-blinded randomized clinical trial enrolled 130 participants aged 18 to 65 years and was conducted in 3 hospitals across China. Treatment-naive patients with newly diagnosed SLE, a high titer of anti-dsDNA antibody, and no major organ involvement were included. The study was started September 1, 2018, and the follow-up was completed September 30, 2021. Data were analyzed from December 1, 2021, to March 31, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized 1:1 to receive oral prednisone (0.5 mg\/kg\/d) and hydroxychloroquine sulfate (5 mg\/kg\/d) (control group) or prednisone (0.5 mg\/kg\/d) and hydroxychloroquine sulfate (5 mg\/kg\/d) plus MMF (500 mg twice daily) (MMF group) for 96 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the proportion of patients presenting with flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment\u2013Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Flare Index. The secondary outcomes included the proportion with lupus low disease activity state at week 96, 36-Item Short Form Health Survey scores before and after treatment, proportion of adverse events (AEs), and changes in SLEDAI-2000 scores and prednisone doses.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 130 randomized patients (mean [SD] age, 34.5 [12.5] years; 112 [86.2%] women), 119 (91.5%) completed the follow-up. The risk of severe flare was significantly lower in the MMF group (7 of 65 [10.8%]) vs the control group (18 of 65 [27.7%]) (relative risk [RR], 0.39 [95% CI, 0.17-0.87]; P<\/jats:italic>\u2009=\u2009.01). Additionally, 1 of 65 patients in the MMF group (1.5%) and 9 of 65 in the control group (13.8%) manifested LN (RR, 0.11 [95% CI, 0.01-0.85]; P<\/jats:italic>\u2009=\u2009.008). Most common serious study drug\u2013related AEs were infections (20 of 65 [30.8%] in the control group and 22 of 65 [33.8%] in the MMF group).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this randomized clinical trial suggest that MMF may reduce the rate of severe flare and lower the incidence of LN in patients with new-onset SLE and a high titer of anti-dsDNA antibody without major organ involvement.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Chinese Clinical Trial Registry: ChiCTR1800017540<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.32131","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T15:04:12Z","timestamp":1726499052000},"page":"e2432131","source":"Crossref","is-referenced-by-count":23,"title":["Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus"],"prefix":"10.1001","volume":"7","author":[{"given":"Yijun","family":"You","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuochao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Second Affiliated Hospital of Shandong First Medical University, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junna","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"11","key":"zoi240966r1","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s10067-013-2330-3","article-title":"Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity.","volume":"32","author":"Andrejevic","year":"2013","journal-title":"Clin Rheumatol"},{"key":"zoi240966r2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2015.00475","article-title":"Mechanisms of kidney injury in lupus nephritis\u2014the role of anti-dsDNA antibodies.","volume":"6","author":"Yung","year":"2015","journal-title":"Front Immunol"},{"key":"zoi240966r3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/328078","article-title":"Systemic lupus erythematosus with and without anti-dsDNA antibodies: analysis from a large monocentric cohort.","volume":"2015","author":"Conti","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"8","key":"zoi240966r4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1191\/096120399680411281","article-title":"Classification and definition of major flares in SLE clinical trials.","volume":"8","author":"Petri","year":"1999","journal-title":"Lupus"},{"key":"zoi240966r5","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3389\/fimmu.2019.01667","article-title":"Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies.","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"zoi240966r6","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/1529-0131(200110)44:10<2342::AID-ART397>3.0.CO;2-8","article-title":"Decreases in anti\u2013double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.","volume":"44","author":"Ho","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"zoi240966r7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/rheumatology\/kead231","article-title":"SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus\u2014an analysis of anti\u2013double-stranded DNA monitoring.","volume":"63","author":"Yeo","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"zoi240966r8","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10067-017-3842-z","article-title":"Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.","volume":"36","author":"Peng","year":"2017","journal-title":"Clin Rheumatol"},{"key":"zoi240966r9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.12659\/AOT.889299","article-title":"Mycophenolate mofetil in liver transplantation: a review.","volume":"18","author":"Kaltenborn","year":"2013","journal-title":"Ann Transplant"},{"issue":"1","key":"zoi240966r10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13075-020-02356-z","article-title":"Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells.","volume":"22","author":"Shigesaka","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"21","key":"zoi240966r11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi240966r12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials.","volume":"70","author":"Palmer","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"zoi240966r13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1756-185X.12179","article-title":"Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.","volume":"16","author":"Yahya","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"zoi240966r14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","article-title":"Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.","volume":"62","author":"Ginzler","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"zoi240966r15","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"zoi240966r16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"zoi240966r17","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/S1473-3099(23)00455-3","article-title":"Overcoming publication and dissemination bias in infectious diseases clinical trials.","volume":"24","author":"Grobusch","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"zoi240966r18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus.","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi240966r19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis.","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi240966r20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus.","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"zoi240966r21","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus.","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240966r22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS).","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi240966r23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36), I: conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"3","key":"zoi240966r24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus.","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi240966r25","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2665-9913(20)30004-7","article-title":"Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"2","author":"Sun","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"zoi240966r26","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"zoi240966r27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"zoi240966r28","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/acr.24901","article-title":"Impact of belimumab on organ damage in systemic lupus erythematosus.","volume":"74","author":"Urowitz","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6 Pt 2","key":"zoi240966r29","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.lpm.2014.03.002","article-title":"Why and how should we measure disease activity and damage in lupus?","volume":"43","author":"Feld","year":"2014","journal-title":"Presse Med"},{"issue":"10188","key":"zoi240966r30","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults.","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"zoi240966r31","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus.","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"zoi240966r32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/ndt\/gfr553","article-title":"Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis trial.","volume":"27","author":"Stoenoiu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"zoi240966r33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrneph.2014.215","article-title":"Treatment of severe lupus nephritis: the new horizon.","volume":"11","author":"Chan","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"20","key":"zoi240966r34","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi240966r35","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis trial.","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"zoi240966r36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1191\/096120399678840927","article-title":"Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.","volume":"8","author":"Gaubitz","year":"1999","journal-title":"Lupus"},{"issue":"8","key":"zoi240966r37","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","article-title":"Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.","volume":"41","author":"Karim","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"3-4","key":"zoi240966r38","first-page":"41","article-title":"Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies.","volume":"139","author":"Bandelier","year":"2009","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"zoi240966r39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2893.1999.00163.x","article-title":"Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro.","volume":"6","author":"Gong","year":"1999","journal-title":"J Viral Hepat"},{"key":"zoi240966r40","first-page":"57","article-title":"Immunosuppressive and long-acting anti-inflammatory activity of mycophenolic acid and derivative, RS-61443.","volume":"30","author":"Allison","year":"1991","journal-title":"Br J Rheumatol"},{"issue":"6","key":"zoi240966r41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil.","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther Drug Monit"},{"issue":"3","key":"zoi240966r42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"zoi240966r43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nep.12136","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia.","volume":"19","author":"Mok","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"zoi240966r44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823522\/you_2024_oi_240966_1725471967.67727.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T15:04:39Z","timestamp":1726499079000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823522"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.32131","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]}}}